These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20065259)

  • 1. FDA approves kallikrein inhibitor to treat hereditary angioedema.
    Thompson CA
    Am J Health Syst Pharm; 2010 Jan; 67(2):93. PubMed ID: 20065259
    [No Abstract]   [Full Text] [Related]  

  • 2. Response time for ecallantide treatment of acute hereditary angioedema attacks.
    Riedl M; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ecallantide for the treatment of acute attacks in hereditary angioedema.
    Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
    N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecallantide for treatment of acute attacks of hereditary angioedema.
    Martello JL; Woytowish MR; Chambers H
    Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
    Banta E; Horn P; Craig TJ
    Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
    Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
    Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
    Gandhi PK; Gentry WM; Bottorff MB
    Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA approves new drug to prevent hereditary angioedema attacks.
    Lavine G
    Am J Health Syst Pharm; 2008 Nov; 65(22):2080. PubMed ID: 18997129
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis.
    Burke S; Petrov A; Johnson J; MacGinnitie A
    Ann Allergy Asthma Immunol; 2011 Aug; 107(2):181-2. PubMed ID: 21802029
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema.
    Hwang JR; Hwang G; Johri A; Craig T
    Immunotherapy; 2019 Dec; 11(17):1439-1444. PubMed ID: 31635497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks.
    Kuhlen J; Guyer A; Morphew T; Tachdjian R; Banerji A
    Ann Allergy Asthma Immunol; 2014 May; 112(5):471-2. PubMed ID: 24630437
    [No Abstract]   [Full Text] [Related]  

  • 13. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
    MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
    Stolz LE; Horn PT
    Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.
    Lehmann A
    Expert Opin Biol Ther; 2008 Aug; 8(8):1187-99. PubMed ID: 18613770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
    Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
    J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.
    Bernstein JA; Qazi M
    Expert Rev Clin Immunol; 2010 Jan; 6(1):29-39. PubMed ID: 20383888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ecallantide in pediatric hereditary angioedema.
    MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
    Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
    Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary angioedema--therapies old and new.
    Morgan BP
    N Engl J Med; 2010 Aug; 363(6):581-3. PubMed ID: 20818894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.